# Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET

> **NCT02631616** · PHASE1 · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 30 (estimated)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Somatostatin

## Key facts

- **NCT ID:** NCT02631616
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-02
- **Primary completion:** 2017-02
- **Final completion:** 2018-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2015-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631616, "Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02631616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*